Rheumatoid arthritis: When should we use rituximab to treat RA?

Nature Reviews Rheumatology

Volumn 7, Issue 7, 2011, Pages 379-380

  Yazici, Yusuf ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; RITUXIMAB;

COMBINATION CHEMOTHERAPY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; JOINT SWELLING; MONOTHERAPY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; PREGNANCY; TREATMENT OUTCOME;

EID: 79959962714     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.79     Document Type: Short Survey

References (9)

1. Yazici, Y. Treatment of rheumatoid arthritis: we are getting there. Lancet 374, 178-180 (2009).
2. Buch, M. H. et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 909-920 (2011).
3. Saunders, S. A. et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 58, 1310-1317 (2008).
4. Soubrier, M. et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 48, 1429-1434 (2009).
5. Gibofsky, A. & Yazici, Y. Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes. Ann. Rheum. Dis. 69, 941-942 (2010).
6. Tak, P. P. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 70, 39-46 (2011).
7. Yazici, Y. & Yazici, H. Tumor necrosis factor a inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis. Clin. Exp. Rheumatol. 26, 449-452 (2008). (Pubitemid 352003214)
8. Yazici, Y., Adler, N. M. & Yazici, H. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. Rheumatology (Oxford) 47, 1054-1057 (2008). (Pubitemid 351865932)
9. Paterson, K. R. Events per person year. Can obscure the true risk of certain adverse drug reactions. BMJ 310, 1470 (1995).